|
|
Article: Multi-site study of potential EC in gear.(emergency contraception from HRA Pharma)
- Article from:
- Contraceptive Technology Update
- Article date:
- May 1, 2007
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Multi-site study of potential EC in gear
Women may have another choice in emergency contraception (EC) if a current multi-site trial of a potential candidate proves successful. HRA Pharma of Paris, France, has initiated a pivotal multicenter Phase III study to evaluate its proprietary second-generation emergency contraceptive.
The open-label investigation will analyze safety and efficacy of the drug, trademarked Ella (CDB-2914), as an emergency contraceptive. Study participants will include women older than age 18 who request EC within 120 hours (five days) of unprotected sexual intercourse or a contraceptive failure. More than 1,000 women are expected ...